Self-emulsifying formulations of DIM-related indoles
Inventors
Zeligs, Michael A. • Jacobs, Irwin C.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed herein are self-emulsifying compositions and formulations of Diindolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.
Core Innovation
The invention features a composition comprising 3,3′-diindolylmethane (DIM) and a carrier containing caprylocaproyl polyoxyl-8 glyceride, lauroyl polyoxyl-32 glyceride, phosphatidyl choline or lysophosphatidyl choline, oleoyl polyoxyl-6 glyceride, and a poloxamer. The poloxamer maintains specified block-mass constraints. Upon dispersion in water or contact with gastrointestinal fluids, the composition emulsifies to form a dispersion of oil-in-water globules.
The formulation maintains DIM solubilization, limits recrystallization, and improves oral bioavailability. Phosphatidylcholine and poloxamer associate with finer oil-in-water dispersions, while poloxamer-containing formulations retain more dissolved DIM during simulated digestion. Human pharmacokinetic data demonstrate increased DIM exposure compared with spray-dried and crystalline forms. Because the background section is omitted, the problem identified there is not explicitly described.
Claims Coverage
The provided claims include one independent claim covering three inventive features.
DIM composition with specified carrier components
The composition comprises DIM and a carrier comprising caprylocaproyl polyoxyl-8 glyceride, lauroyl polyoxyl-32 glyceride, phosphatidyl choline or lysophosphatidyl choline, oleoyl polyoxyl-6 glyceride, and a poloxamer.
Poloxamer block-mass constraints
The poloxamer has a hydrophobic block with a molecular mass greater than 50% of the total molecular mass of the poloxamer and a hydrophilic block with a molecular mass less than 2,250 Daltons.
Formation of oil-in-water globules
Upon dispersion in water or contact with gastrointestinal fluids, the composition emulsifies to form a dispersion of oil-in-water globules.
The independent claim covers the specified DIM and carrier composition, the poloxamer block-mass constraints, and the formation of an oil-in-water globule dispersion upon contact with water or gastrointestinal fluids.
Stated Advantages
Phosphatidylcholine and poloxamer are associated with finer oil-in-water dispersions, smaller globules, and reduced DIM recrystallization.
In simulated digestion, poloxamer-containing Formulation G retained more dissolved DIM than formulations without poloxamer.
Human pharmacokinetic data for Formulation D show substantially increased DIM exposure and higher plasma concentrations compared with spray-dried and crystalline DIM, with mean Cmax and AUC values of 363.2 ng/mL and 1507.2 ngh/mL, respectively.
Controlled storage results show that Formulation G maintains approximately 12% DIM content through three months, supporting API and excipient compatibility and stability.
The formulation is intended to maintain DIM solubilization, limit recrystallization, and improve oral bioavailability.
Documented Applications
The document describes oral and topical dosage forms, as well as combination formulations.
The formulation is described for pharmaceutical, nutraceutical, and topical applications, including DIM SMEDDS delivery emulsifying into an oil-in-water globule dispersion.
Interested in licensing this patent?